May 8th 2020
Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.
January 3rd 2016
Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.